NASDAQ:OPGN
OpGen, Inc. Stock News
$0.535
+0.0201 (+3.90%)
At Close: Apr 29, 2024
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2022 Results - Earnings Call Transcript
11:15pm, Thursday, 12'th May 2022
OpGen, Inc. (NASDAQ:OPGN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Alyssa Factor - Edison Group Oliver Schacht - President and CEO Albert Weber - CFO Conference C
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
06:48pm, Thursday, 12'th May 2022
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
11:30am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
ROCKVILLE, Md., April 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat
OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel
11:30am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
ROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinf
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
11:25pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
09:04pm, Tuesday, 29'th Mar 2022
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen's (OPGN) CEO Oliver Schacht on Q4 2021 Results - Earnings Call Transcript
08:29pm, Tuesday, 29'th Mar 2022
OpGen's (OPGN) CEO Oliver Schacht on Q4 2021 Results - Earnings Call Transcript
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
08:05pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinf
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
11:05pm, Thursday, 24'th Mar 2022 Zacks Investment Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
11:30am, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
11:30am, Tuesday, 15'th Mar 2022 GlobeNewswire
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, March 29 th , 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates
12:55am, Tuesday, 01'st Mar 2022 Zacks Investment Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -11.54% and 2.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology
09:30pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
12:30pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat i
